Heron Therapeutics, Inc. (HRTX) stock forecast & analysis
1 analysis. Latest: .
Market Scanner’s AI analysis of Heron Therapeutics, Inc. (HRTX), updated August 2026: HRTX faces bearish technicals and withdrawn guidance amid CINVANTI patent risks and strategic review.
Summary
HRTX faces bearish technicals and withdrawn guidance amid CINVANTI patent risks and strategic review.
Recent analyses for HRTX covered significant price declines and bearish technical indicators, including trading below key moving averages and Bollinger Bands. The company reported a Q2 loss, missed revenue estimates, and withdrew its 2026 guidance due to CINVANTI patent risks and an ongoing strategic review. Despite these headwinds, some aspects of the earnings call highlighted revenue growth.
HRTX news & sentiment
News reports highlighted a Q2 loss, missed revenue estimates, and withdrawn guidance due to patent risks and a strategic review, although some call highlights mentioned revenue growth. Social media discussions were not covered in the provided notes.
HRTX technical picture
The stock has experienced significant declines, trading well below its 50-day and 200-day moving averages, confirming a bearish trend. Momentum indicators are in oversold territory, with the RSI below 30 and the MFI indicating selling pressure, though the MACD has recently crossed above its signal line.
Fundamentals
The company's trailing twelve-month revenue was $150.71 million, with year-over-year quarterly revenue growth at -10.8%. The trailing twelve-month EPS was -0.18, with a negative profit margin of -20.53% and an operating margin of -13.73%.
Factors discussed — upside
- Some earnings call highlights indicated revenue growth.
- TTM gross profit is $94.65 million.
- TTM revenue stands at $150.71 million.
Factors discussed — risks
- Significant price declines over 1-week, 1-month, and 3-month periods.
- Trading significantly below 50-day and 200-day SMAs.
- RSI in oversold territory (24.27).
- MFI below 50, indicating selling pressure.
- Withdrew 2026 guidance citing CINVANTI patent risks and strategic review.
- Technical indicators
- Financial performance
- Guidance withdrawal
- Patent risks
Summary updated .
Analyses
Recent HRTX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Heron Therapeutics, Inc.?
- Some aspects of the earnings call highlighted revenue growth, and the company's trailing twelve month revenue and gross profit stand at $150.71 million and $94.65 million, respectively.
- What are the risks for Heron Therapeutics, Inc.?
- The company has experienced significant price declines, trading below key moving averages and in oversold territory according to technical indicators. Furthermore, HRTX withdrew its 2026 guidance, citing CINVANTI patent risks and an ongoing strategic review.
- Is Heron Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Heron Therapeutics, Inc. examined factors on both sides. Discussed upside: Some aspects of the earnings call highlighted revenue growth, and the company's trailing twelve month revenue and gross profit stand at $150.71 million and $94.65 million, respectively. Discussed risks: The company has experienced significant price declines, trading below key moving averages and in oversold territory according to technical indicators. Furthermore, HRTX withdrew its 2026 guidance, citing CINVANTI patent risks and an ongoing strategic review. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Heron Therapeutics, Inc.?
- News reports highlighted a Q2 loss, missed revenue estimates, and withdrawn guidance due to patent risks and a strategic review, although some call highlights mentioned revenue growth. Social media discussions were not covered in the provided notes.
- Bundles used
- gemini-low-v2
Sign in to read every HRTX.US report in the library
Each analysis includes the full reasoning, dissent, and decision rationale from the structured AI pipeline.